1. Gordon DA, Hastings DE: Rheumatology, second edition. in
Klippel JH, Dieppe PA(eds): Rheumatoid arthritis, clinical
features of early, progressive and late disease. London, 1998,
5:3.1-3.4s.
2. Matteson EJ, Cohen MD, Conn DL: Rheumatology, second
edition. in Klippel JH, Dieppe PA(eds): Rheumatoid arthritis,
clinical features and systemic involvment. London, 1998, 5:4.1-
4.8s.
3. Gaston H: Rheumatology, second edition. in Klippel JH, Dieppe
PA(eds): Rheumatoid arthritis, cellular immunity in RA. London,
1998, 5:10.1-10.6s.
4. Bresnihan B: Pathogenesis of joint damage in rheumatoid
arthritis. J Rheumatol 1999; 26: 717-9.
5. Wooley P: Rheumatology, second edition. in Klippel JH, Dieppe
PA(eds): Rheumatoid arthritis, animal model of arthritis. London,
1998, 5:8.1-8.6s.
6. Virkamaki A, Ueki K, Kahn CR: Protein-protein interaction in
insulin signaling and the molecular mechanisms of insulin
resistance. J Clin Invest 1999; 103: 931-43.
7. Roach P, Zick Y, Formisane P, Accili D, Taylor SI, Gorden P: A
novel human IR gene mutation uniquely inhibits insulin binding
without impairing posttranslational processing. Diabetes 43:
1096-1102, 1994.
8. Arnett FC, Edworthy SM, Bloch DA et al: The American
Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. J Rheumatol 1988; 31: 315-
24.
9. Matthews DR, Hosker JP, Turner RC: Homeostasis Model
Assesment: insulin resistance and β-cell function from fasting
plasma glucose and insulin concentrations in man. Diabetologia
1985; 28: 412-9.
10. Matsuda M, DeFronzo RA:Insulin sensitivity indices obtained
from oral glucose tolerance testing. Diabetes Care 1999, 22:
1462-70.
11. Genuth S, Brownlee MA, Kuller LH, Samols E, Saudek CD,
Sherwin R: Consensus development conference on insülin
resistance. Diabetes Care 1998; 21(2): 310.
12. Festa A, D’Agostino R, Hales CN, Mykanen L, Haffner SM:
Heart rate in relation to insulin sensitivity and insulin secretion in
nondiabetic subject. Diabetes Care 2000; 23: 624-8.
13. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ,
Rewers M, Mykanen L, Karter AJ, Hamman R, Saad MF: Insulin
sensitivity and acute insulin response in Africans- Americans,
Non-Hispanic Whites, and Hispanics with NIDDM: The Insulin
Resistance Atherosclerosis Study. Diabetes 1997; 46: 63-9.
14. Svenson H: Insulin and atheroma 20 yrs perspective. Diabetes
Care 1990; 13(6): 631-54.
15. Tanaka T, Itoh H, Doi K, Fukunaga Y, Hosoda K, Shintani M,
Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito
T, Inoue G, Nishimura H, Yoshimasa Y, Nakao K: Down C. Top, ark.
84
regulation of peroxisome proliferator-activated receptorgamma
expression by inflammatory cytokines and its reversal by
thiazolidinediones. Diabetologia 1999; 42(6):702-10.
16. Amrani A, Jafarian-Tehrani M, Mormede P, Durant S, Pleau JM,
Haour F, Dardenne M, Homo-Delarche F: Interleukin-1 effect on
glycemia in the non-obese diabetic mouse at the pre-diabetic
stage. J Endocrinol 1996; 148(1): 139-48.
17. Ling PR, Istfan NW, Colon E, Bistrian BR: Differential effects of
interleukin-1 receptor antagonist in cytokine- and endotoxintreated rats. Am J Physiol 1995; 268(2): E255-61.
18. Ling PR, Bistrian BR, Mendez B, Istfan NW: Effects of systemic
infusions of endotoxin, tumor necrosis factor, and interleukin-1
on glucose metabolism in the rat: relationship to endogenous
glucose production and peripheral tissue glucose uptake.
Metabolism 1994; 43(3): 279-84.
19. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C,
Tataranni PA: High white blood cell count is associated with a
worsening of insulin sensitivity and predicts the development of
type 2 diabetes. Diabetes 2002; 51: 455-61.
20. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH,
Resnick HE, Tracy RP: The relation of markers of inflammation
to the development of glucose disorders in the elderly: The
Cardiovascular Health Study. Diabetes 2001; 50: 2384-9.
21. Festa A, D’Agostino R, Tracy RP, Haffner SM: Elevated levels of
acute-phase proteins and plasminogen activator inhibitor-1 predict
the development of type 2 diabetes: The Insulin Resistance
Atherosclerosis Study. Diabetes 2002; 51: 1131-7.
22. Thomas HE, Darwiche R, Corbett JA, Kay TWH: Interleukin-1
plus –γ-interferon-induced pancreatic ß-cell dysfunction is
mediated by ß-cell nitric oxide production. Diabetes 2002; 51:
311-6.
23. Andersen HU, Jorgensen KH, Egeberg J, Mandrup-Poulsen T,
Nerup J: Nicotinamide prevents interleukin-1 effects on
accumulated insulin release and nitric oxide production in rat
islets of Langerhans. Diabetes 1994; 43: 770-7.
24. McDaniel ML, Hughes JH, Wolf BA, Easom RA, Turk JW:
Descriptive and mechanistic considerations of interleukin 1 and
insulin secretion. Diabetes 1988; 37: 1311-5.
25. Comens PG, Wolf BA, Unanue ER, Lacy PE, McDaniel ML:
Interleukin 1 is potent modulator of insulin secretion from
isolated rat islets of Langerhans. Diabetes 1987; 36: 963-70.
26. Zawalich WS, Diaz VA: Interleukin 1 inhibits insulin secretion
from isolated perifused rat islets. Diabetes 1986; 35(10): 1119-23.
27. Ma Z, Landt M, Bohrer A, Ramanadham S, Kipnis D M, Turk J:
Interleukin-1 reduces the glycolytic utilization of glucose by
pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism. J Biol
Chem 1997; 272 (28): 17827-35.
28. Ma Z, Ramanadham S, Corbett JA, Bohrer A, Gross RW,
McDaniel ML, Turk J: Interleukin-1 enhances pancreatic islet
arachidonic acid 12-lipoxygenase product generation by
increasing substrate availability through a nitric oxide-dependent
mechanism. J Biol Chem 1996; 271 (2): 1029-42.
29. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S,
Fujiwara T, Horikoshi H, Serizawa N: Troglitazone prevents the
inhibitory effects of inflammatory cytokines on insulin-induced
adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994;
135(5): 2279-82.
30. Ji JD, Cheon H, Jun JB, Choi SJ, Kim YR, Lee YH, Kim TH,
Chae IJ, Song GG, Yoo DH, Kim SY, Sohn J: Effects of
peroxisome proliferator-activated receptor-gamma (PPARgamma) on the expression of inflammatory cytokines and
apoptosis induction in rheumatoid synovial fibroblasts and
monocytes. J Autoimmun 2001; 17(3): 215-21.
Thank you for copying data from http://www.arastirmax.com
